• Conjustar

  Participated · Series A · Jan 2024

  Xinglian Peptide (星联肽) develops protein-conjugate therapeutics, using a combination of introduced and in-house R&D to rapidly build its pipeline. The company currently has three candidates in preclinical development. It expects its first product to enter clinical research in 2024. The program is positioned to deliver more effective and safer oncology treatments for patients, per the company statement. Recently the company completed a RMB 90 million Pre‑A financing, strengthening its financial position for near-term development. Tianjin Xinglian Peptide Biotech (天津星联肽生物科技有限公司) was founded in February 2022 and positions itself as a platform developer of protein/peptide conjugate therapeutics, emphasizing PDCs. The team reports deep XDC drug‑development and project‑management experience and currently has three products in preclinical development. Its lead PDC, SC‑101, targets Nectin‑4 and is presented as having efficacy and safety advantages versus same‑target ADCs at comparable dosing frequency and potential to be Best‑in‑Class. SC‑101 is progressing toward an IND submission expected in the second half of the year and plans to enter Phase I in 2024. The company recently completed a financing to support IND development for two PDC candidates and to build an early R&D platform. Tianjin Xinglian Peptide (天津星联肽生物科技有限公司) operates a peptide-drug conjugate (PDC) drug R&D platform, combining introduced technologies with in-house research to rapidly build its pipeline. The company was incubated and established by the 复健资本新药创新基金 (the fund named in the article). As of the report, Xinglian Peptide has three programs in preclinical development. The firm completed a seed financing of RMB 45.5 million in February 2022 to support its R&D activities. It expects its first product to enter clinical research in 2024. The company aims to deliver more effective and safer treatments for cancer patients.

No current team members are available.